Abivax Stock Surges on Positive Ulcerative Colitis Drug Data

By EC Assets · Published 30 June 2026

Abivax SA ADR shares increased significantly in after-hours trading. The company announced positive results for its experimental drug obefazimod. This development follows previous concerns regarding drug safety. Abivax SA ADR shares jumped 18.5% in after-hours trading Monday. Other reports indicated a stock jump of 28% in after-hours trading on Monday. One report noted a nearly 27% surge in overnight trading for the company. The positive results came from the ABTECT Maintenance Part 2 trial. Obefazimod is an experimental drug for ulcerative colitis. Earlier, Abivax's stock had experienced a decline following disappointing maintenance trial data. There were also reports of the stock plummeting 40 percent due to safety concerns in clinical trials. Unexpected cancer cases reportedly emerged in a crucial trial, causing a plunge in shares. Despite these previous setbacks, the stock remains up approximately 1,000% over the past 12 months. A French biotech stock also soared 25% after new data on experimental medicine, which aligns with Abivax's recent news. The recent positive late-stage results for obefazimod appear to have eased earlier drug safety concerns. This has driven the recent surge in the stock price. The company's announcement of positive results for its obefazimod drug is a key factor in the market's reaction. Investors will likely monitor further announcements regarding obefazimod's regulatory path and future trial data. Developments in the broader biotechnology sector concerning experimental drug trials for chronic conditions may also influence sentiment. This article is intended for informational purposes only. It does not constitute investment advice.